Business
Outlook Therapeutics Reports Financial Results for First Quarter Fiscal Year 2022 and Provides Corporate Update
Outlook Therapeutics remains on track to submit new U.S. FDA Biologics License Application (BLA) for first ophthalmic formulation of bevacizumab Commercial
About this update from Outlook Therapeutics, Inc.
[{"type":"text","content":"Outlook Therapeutics remains on track to submit new U.S. FDA Biologics License Application (BLA) for first ophthalmic formulation of bevacizumab Commercial launch planning underway Financed through the anticipated approval of the ONS-5010 BLA ISELIN, N.J., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced recent corporate highlights and financial results for its fiscal first quarter ended December 31, 2021. Recent Corporate Highlights Expanded commercial team with appointment of SVP, Commercial Operations;Closed a $57.5 million gross proceeds equity offering, including full exercise of underwriter’s option to purchase additional shares;Presented data at scientific conferences including the Retina Subspecialty Day, American Academy of Ophthalmology (AAO) 2021 Annual Conference, the Eyecelerator@AAO 2021 Conference Retina Showcases, the 2021 American Society of Retina Specialists (ASRS) Annual Meeting, the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase, the EURETINA Virtual 2021 Medical Conference, the Asia-Pacific Vitreo-Retina Society (APVRS) Congress and the International Congress on OCT and OCT Angiography in Rome (ICOOR/ FLORetina) Symposia; andReported positive 12-month safety data from pivotal Phase 3 NORSE TWO trial, which reinforce strong safety profile consistent with previous trials of ONS-5010 ophthalmic bevacizumab and with prior published data on ophthalmic use of bevacizumab. “We continue to build on the solid foundation laid over the course of the past year to position Outlook Therapeutics for a transformational year ahead. With the targeted submission of our BLA just around the corner, we are ramping up our commercial launch planning and expertise as we look to optimize the benefit and potential positive impact ONS-5010 which, if approved, will provide to the retina community a differentiated anti-VEGF offering. Additionally, with a strong balance sheet coupled with the encouraging data amassed for our BLA submission, we look forward to driving this exciting opportunity forward,” commented Mr. C. Russell Trenary III, President and Chief Executive Officer of Outlook Therapeutics. ONS-5010 / LYTENAVA™ (bevac...